APA (7th ed.) Citation

Sheng, L., Liu, H., Zhang, X., Ding, K., Ma, J., Peng, H., . . . Fan, L. (2025). Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma. Blood Cancer Journal, 15(1), 1. https://doi.org/10.1038/s41408-025-01278-w

Chicago Style (17th ed.) Citation

Sheng, Lixia, et al. "Prospective Phase II Trial of First-line Rituximab, Methotrexate, and Orelabrutinib (R-MO) in Primary Central Nervous System Lymphoma." Blood Cancer Journal 15, no. 1 (2025): 1. https://doi.org/10.1038/s41408-025-01278-w.

MLA (9th ed.) Citation

Sheng, Lixia, et al. "Prospective Phase II Trial of First-line Rituximab, Methotrexate, and Orelabrutinib (R-MO) in Primary Central Nervous System Lymphoma." Blood Cancer Journal, vol. 15, no. 1, 2025, p. 1, https://doi.org/10.1038/s41408-025-01278-w.